Mobic Market Share Doubles Following Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott's non-steroidal anti-inflammatory drug Mobic (meloxicam) is showing strong growth in the wake of the withdrawal of Merck's Vioxx, Verispan data released Oct. 13 show